title: Prevention of post-ERCP pancreatitis.
abstract: Pancreatitis is one of the most common complications of endoscopic retrograde cholangiopancreatography (ERCP). A variety of patient-related and procedure-related factors have been identified to risk-stratify patients. Several measures can be undertaken in order to decrease the risk of post-ERCP pancreatitis in high-risk groups. These measures include pancreatic duct stenting and rectal indomethacin, amongst others.
authors.affiliation: Temple University School of Medicine, 3401 N. Broad St., Suite 830 Parkinson Pavilion, Philadelphia, PA, 19140, USA, jennifer.maranki@tuhs.temple.edu.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Maranki
authors.forename: Paul
authors.initials: P
authors.lastname: Yeaton
mesh_terms: D000285:Administration, Rectal; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects* / Q000379:methods; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D010183:Pancreatic Ducts; D010195:Pancreatitis / Q000209:etiology / Q000517:prevention & control*; D018579:Patient Selection; D011480:Protease Inhibitors / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors; D015607:Stents; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D006728:Hormones; D011480:Protease Inhibitors; D014665:Vasodilator Agents; D007213:Indomethacin